Long‐term results of up to 6 years of mitomycin‐c augmented non‐penetrating deep sclerectomy for pseudoexfoliation glaucoma

Abstract

Listen

Translate article

PurposeTo evaluate the long‐term efficacy of mitomycin‐c augmented non‐penetrating deep sclerectomy (NPDS) in patients with pseudoexfoliation glaucoma.MethodsIn this retrospective single‐center study a total of 72 eyes of 63 patients with pseudoexfoliation glaucoma were included. Perioperative and postoperative complications, additional procedures including laser goniopuncture, needling, selective laser trabeculoplasty (SLT) were recorded. Complete and partial surgical success were defined as an intraocular pressure (IOP) <18 mmHg and IOP between 18‐21 mmHg with or without medications, respectively.ResultsThe follow‐up time was 26.40 ± 20.06 months (range 1–80). Preoperative and postoperative IOP were 26.53 ± 7.71 and 18.69 ± 6.58 mmHg, respectively (p < 0.001). Preoperative and postoperative last visit mean RNFL were 61.82 ± 17.54 and 62.55 ± 17.39 micrometers, respectively (p = 0.081). The success rate for the IOP of 18–21 and <18 after first year were 88 and 87%, respectively, and after second years were 88 and 71%, respectively. The success rate for the IOP < 18 after 3 years was 60%, after 4 years was 55%, after 5 years was 49%, and after 6 years was 37%. The success of NPDS is not affected by age, gender, preoperative application of SLT, cup/disc ratio, preoperative IOP and medication numbers (p > 0.05). Hypotony was observed in 19 eyes. There were no serious complications including hypotony induced maculopathy, choroidal detachment, blebitis, and endophthalmitis.ConclusionsMitomycin‐c augmented deep sclerectomy is almost as effective as trabeculectomy in long‐term management of intraocular pressure in patients with pseudoexfoliative glaucoma in addition with lower complication rates with its well‐known excellent safety profile.